pocketful logo
Nectar Lifescience Ltd logo

Nectar Lifescience Ltd

NSE: NECLIFE BSE: 532649

₹13.34

(-1.33)%

Sun, 01 Feb 2026, 05:27 pm

mtf coin illustrationMTF 5x

nectar lifescience ltd History

1995

  • Nectar Lifesciences Limited was incorporated as Surya Medicare Limited
  • PSIDC invested in 33,30,000 Equity Shares of the company

1996

  • The company proposed a public issue of 6,400,000 Equity Shares
  • The company filed the offer document with SEBI

1997

  • The company commenced business with the commercial production of Oral Bulk Drugs

1998

  • The project was fully completed and the company started production of Sterile Bulk Drugs

1999

  • The company added formulation facilities by setting up a vial filling section

2000

  • The company undertook an expansion increasing the installed capacity of the plant

2001

  • Swiss Technology Venture Capital Fund invested Rs 64 million
  • The company installed a new Crystalline section
  • The new Crystalline section commenced production in October

2002

  • The subsidiary Chempharma was incorporated under the laws of Sri Lanka

2003

  • The entire shareholding of PSIDC was bought back by the Promoters
  • The company filed the Draft Red Herring Prospectus with SEBI

2004

  • The company changed its name to Nectar Lifesciences Limited
  • The company planned a public issue of 3,870,000 Equity Shares

2005

  • The Promoters acquired all the shares held by Swisstech

2007

  • Mr Basant Kumar Goswami was appointed as an additional director Independent director

2008

  • The Company split its face value from Rs10 to Rs1

2009

  • The company recommended a Final Dividend of Re 0.10 per equity share
  • Nectar Lifesciences elevated to the rank of 365 in the list of India's top companies

2010

  • The Company declared an interim dividend of Re 0.25 per equity share
  • NecLife granted Certificate of Suitability for Cefuroxime Axetil in European Union

2011

  • NecLife announced receipt of Japanese MOH approval for Cefuroxime Axetil
  • NecLife announced receipt of South Africa MCC approval for Ceftriaxone
  • The Company recommended a 10% Final Dividend
  • NecLife received European cGMP Approval for its Cephalosporin Formulation Facility

2012

  • NecLife granted Certificate of Suitability for Cefuroxime Sodium in European Union
  • The Company recommended a 10% Final Dividend
  • Mr Harparkash Singh Gill was appointed as a Wholetime Director designated as President Operation and Director

2013

  • Mr Dinesh Dua was appointed as an Additional Director and Wholetime Director designated as Chief Executive Officer

2014

  • Mr Sanjiv Goyal received the Outstanding Entrepreneurship of the Year award from Asia Pacific Enterprise Awards
  • NecLife received European cGMP Approval for its Orals and Injectables Cephalsporins FDF Facility

2015

  • Nectar Lifesciences Ltd was honoured with the NECA 2015 Award.

2019

  • Nectar Biopharma launched a generic diabetes treatment drug in India.

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

pocketful logo

2022-25 Pocketful. All rights reserved, Built with in India

Version -5.76

app image 1app image 2

Stocks:

AllABCDEFGHIJKLMNOPQRSTUVWXYZ

Explore

Calculatorsfooter arrow down icon
Popular Calculatorsfooter arrow down icon
Group Stocksfooter arrow down icon

Others:

NSEBSECDSLNSDLSEBIMCXMSEINCDEXNSE IFSCINDIA INXAccount Closure FormDP Investor CharterBroker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800